Active Filter(s):
Details:
Under the collaboration, Tevard will utilize its two unique tRNA-based discovery platforms focused on mRNA Stabilization and Nonsense Codon Suppression to discover and advance novel drug candidates for the treatment of Dravet syndrome and other genetic epilepsies.
Lead Product(s): tRNA-based gene therapies
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Zogenix
Deal Size: $115.0 million Upfront Cash: $10.0 million
Deal Type: Collaboration December 03, 2020